NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

DBV Technologies S.A (NASDAQ: DBVT)

 
DBVT Technical Analysis
5
As on 3rd Jul 2025 DBVT STOCK Price closed @ 11.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.94 & Strong Buy for SHORT-TERM with Stoploss of 0.84 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

DBVTSTOCK Price

Open 10.90 Change Price %
High 11.99 1 Day 1.30 12.62
Low 10.55 1 Week 3.08 36.15
Close 11.60 1 Month 2.00 20.83
Volume 29062 1 Year 10.73 1233.33
52 Week High 11.48 | 52 Week Low 0.47
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
LCID 2.16 5.37%
HCTI 0.03 50.00%
NVDA 159.34 1.33%
LMDX 0.02 0.00%
AKTS 0.04 0.00%
PLUG 1.47 5.00%
WINT 0.93 20.78%
BTBT 2.94 11.79%
LILM 0.05 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
TBIO 0.30 500.00%
NBSTU 12.99 220.74%
NDRAW 0.03 200.00%
HCVIU 9.00 159.37%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
CTHR 0.22 -77.08%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
AXDX 0.03 -66.67%
TFFP 0.06 -62.50%
HEPA 0.12 -62.50%
 
 
DBVT
Daily Charts
DBVT
Intraday Charts
Whats New @
Bazaartrend
DBVT
Free Analysis
 
DBVT Important Levels Intraday
RESISTANCE14.37
RESISTANCE13.48
RESISTANCE12.93
RESISTANCE12.38
SUPPORT10.82
SUPPORT10.27
SUPPORT9.72
SUPPORT8.83
 
DBVT Forecast July 2025
4th UP Forecast11.97
3rd UP Forecast11.85
2nd UP Forecast11.78
1st UP Forecast11.7
1st DOWN Forecast11.5
2nd DOWN Forecast11.42
3rd DOWN Forecast11.35
4th DOWN Forecast11.23
 
DBVT Weekly Forecast
4th UP Forecast11.81
3rd UP Forecast11.74
2nd UP Forecast11.70
1st UP Forecast11.66
1st DOWN Forecast11.54
2nd DOWN Forecast11.50
3rd DOWN Forecast11.46
4th DOWN Forecast11.39
 
DBVT Forecast2025
4th UP Forecast35.42
3rd UP Forecast27.78
2nd UP Forecast23.06
1st UP Forecast18.34
1st DOWN Forecast4.86
2nd DOWN Forecast0.14
3rd DOWN Forecast-4.58
4th DOWN Forecast-12.22
 
 
DBVT Other Details
Segment EQ
Market Capital 346844864.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
DBVT Address
DBVT
 
DBVT Latest News
 
Your Comments and Response on DBV Technologies S.A
 
DBVT Business Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. Address: 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service